Finely ground flaxseed powder ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 299 | Cystic fibrosis | 1 |
299. Cystic fibrosis
Clinical trials : 1,696 / Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02014181 (ClinicalTrials.gov) | July 2012 | 27/11/2013 | Flaxseed Modulates Inflammation and Oxidative Stress in CF | Flaxseed Modulates Oxidative Stress and Inflammatory Biomarkers in Stable Patients With Cystic Fibrosis and Healthy Controls | Cystic Fibrosis;Oxidative Stress;Inflammation | Dietary Supplement: finely ground flaxseed powder | University of Pennsylvania | NULL | Completed | 18 Years | 64 Years | Both | 10 | Phase 1 | United States |